BIOMAT Database Logo BIOMAT Database Logo

New highly potent and selective adenosine A(3) receptor antagonists. 2004

Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
Respiratory Disease Area, Novartis Horsham Research Center, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK. neil.press@pharma.novartis.com

A class of potent, selective adenosine A(3) receptor antagonists was obtained via optimisation of the screening hit N-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide. Structural modifications of this hit revealed very quickly that a 5-(pyridin-4-yl) substituent on the 2-aminothiazole ring was optimal for high potency at the adenosine A(3) receptor. Structure activity relationship studies led to both potent and selective A(3) receptor antagonists, including N-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide, a highly potent aden-osine A(3) receptor antagonist with greater than 100- fold selectivity against the related adenosine receptors. As well as demonstrating selective in vitro binding on the human A(3) adenosine receptor, this compound was also shown to selectively block the rat A(3) receptor in vivo. This important new compound can be readily synthesised in four steps from commercially available starting materials.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D058918 Adenosine A3 Receptor Antagonists Compounds that selectively bind to and block the activation of ADENOSINE A3 RECEPTORS.

Related Publications

Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
New potent and selective human adenosine A(3) receptor antagonists.
December 2000, Trends in pharmacological sciences,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.
May 2009, Bioorganic & medicinal chemistry,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
A structural study of new potent and selective antagonists to the A2B adenosine receptor.
October 2005, Acta crystallographica. Section B, Structural science,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists.
November 1999, Journal of medicinal chemistry,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.
April 2011, Bioorganic & medicinal chemistry letters,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.
January 2011, Journal of medicinal chemistry,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
New highly potent bradykinin B2 receptor antagonists.
September 1991, Agents and actions,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
Bimorphinans as highly selective, potent kappa opioid receptor antagonists.
February 1987, Journal of medicinal chemistry,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists.
June 2002, Journal of medicinal chemistry,
Neil J Press, and Thomas H Keller, and Pamela Tranter, and David Beer, and Ken Jones, and Alexander Faessler, and Richard Heng, and Christine Lewis, and Trevor Howe, and Peter Gedeck, and Lazzaro Mazzoni, and John R Fozard
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
March 2008, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!